Specialty Pharmacy News Roundup: March 2023

Kroger Specialty Pharmacy was selected by Genentech as one of their Network Specialty Pharmacies to dispense ALECENSA®, GAVRETO®, and ROZLYTREK® for the treatment of non-small cell lung cancer, expanding its extensive list of specialty medications in Oncology.

As the largest independent specialty pharmacy by provider choice, Kroger Specialty Pharmacy offers comprehensive therapy-management programs as well as injectable and oral pharmaceutical treatments for Oncology – as well as Dermatology, HIV, Hepatitis C, Multiple Sclerosis, Rheumatoid Arthritis, Growth Hormone Deficiency, Hunters Syndrome, Hemophilia, IVIG, HAE plus others. Kroger Specialty Pharmacy services patients in all 50 states and Puerto Rico and is ACHC and URAC Accredited in numerous sites.

BioMatrix Specialty Pharmacy (BioMatrix) recently announced that it is enhancing and expanding the company’s specialty infusion services and enhanced manufacturer program services, including product commercialization and HUB services.

As part of this strategy, effective February 17, 2023, BioMatrix divested certain pharmacy assets to CVS Specialty and will no longer distribute traditional specialty oral and self-injectable medications. BioMatrix will concentrate on servicing patients with bleeding disorders, receiving immune globulin (Ig) therapies and other specialty infusion medications in addition to providing high-touch patient access services and programs for our manufacturer partners.

BioMatrix offers comprehensive, nationwide specialty pharmacy services and digital health technology solutions for patients with chronic, difficult to treat conditions. The company offers a tailored approach for a wide range of therapeutic categories, improving health and empowering patients to experience a higher quality of life.

Biologics by McKesson and Onco360 were selected by Stemline Therapeutics Inc., as limited distribution network specialty pharmacy providers for ORSERDU™ (elacestrant), which is an estrogen receptor antagonist indicated for the treatment of postmenopausal women or adult men, with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy.

Biologics by McKesson and Onco360 were also selected by Lilly as a specialty pharmacy providers for JAYPIRCA™ (pirtobrutinib) for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy including a BTK inhibitor.

Onco360 was selected by Taiho Oncology to be a specialty pharmacy partner for Lytgobi® (futibatinib), which is a kinase inhibitor indicated for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements.

Takeaway: AMI’s Specialty Pharmacy Database continually monitors and tracks all limited and exclusive pharmacy distribution agreements